T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

NCT03190967 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
12
Enrollment
NIH
Sponsor class

Stopped The phase II portion was never started as we could no longer get the drug from the manufacturer.

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)